- Home
- TILE vs XERS Comparison
TILE vs XERS Comparison
Compare TILE & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TILE
- XERS
- Stock Information
- Founded
- TILE 1973
- XERS 2005
- Country
- TILE United States
- XERS United States
- Employees
- TILE N/A
- XERS N/A
- Industry
- TILE Home Furnishings
- XERS Biotechnology: Pharmaceutical Preparations
- Sector
- TILE Consumer Discretionary
- XERS Health Care
- Exchange
- TILE Nasdaq
- XERS Nasdaq
- Market Cap
- TILE 1.6B
- XERS 1.3B
- IPO Year
- TILE N/A
- XERS 2018
- Fundamental
- Price
- TILE $26.60
- XERS $8.12
- Analyst Decision
- TILE Buy
- XERS Strong Buy
- Analyst Count
- TILE 1
- XERS 7
- Target Price
- TILE $32.00
- XERS $8.00
- AVG Volume (30 Days)
- TILE 513.0K
- XERS 2.2M
- Earning Date
- TILE 10-31-2025
- XERS 11-07-2025
- Dividend Yield
- TILE 0.15%
- XERS N/A
- EPS Growth
- TILE 43.35
- XERS N/A
- EPS
- TILE 1.62
- XERS N/A
- Revenue
- TILE $1,352,215,000.00
- XERS $246,025,000.00
- Revenue This Year
- TILE $7.40
- XERS $43.89
- Revenue Next Year
- TILE $5.17
- XERS $20.40
- P/E Ratio
- TILE $16.53
- XERS N/A
- Revenue Growth
- TILE 6.26
- XERS 35.62
- 52 Week Low
- TILE $17.24
- XERS $2.82
- 52 Week High
- TILE $30.20
- XERS $8.51
- Technical
- Relative Strength Index (RSI)
- TILE 39.99
- XERS 55.09
- Support Level
- TILE $26.24
- XERS $7.78
- Resistance Level
- TILE $27.40
- XERS $8.46
- Average True Range (ATR)
- TILE 0.64
- XERS 0.33
- MACD
- TILE -0.33
- XERS -0.05
- Stochastic Oscillator
- TILE 14.29
- XERS 51.27
About TILE Interface Inc.
Interface Inc is engaged in the design, production, and sale of carpet tiles. It also provides Luxury Vinyl tiles and rubber flooring. The company mainly targets corporate and noncorporate office markets, including government, education, healthcare, hospitality, and retailers. Its geographical segments include the Americas, Europe, and Asia-Pacific. It has two operating and reportable segments- namely Americas (AMS) and Europe, Africa, Asia and Australia (collectively EAAA). Key revenue is generated from AMS segment.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).